2. Search Result
Search Result
Results for "

muscle wasting

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112288
    C188-9
    Maximum Cited Publications
    32 Publications Verification

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
    C188-9
  • HY-P99388
    Trevogrumab
    1 Publications Verification

    REGN-1033; SAR391786

    		 TGF-beta/Smad Metabolic Disease
    Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
    Trevogrumab
  • HY-P99370
    Landogrozumab
    1 Publications Verification

    LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)

    		 TGF-beta/Smad Inflammation/Immunology Cancer
    Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
    Landogrozumab
  • HY-W184800
    MuRF1-IN-2

    		Bacterial E1/E2/E3 Enzyme Inflammation/Immunology
    MuRF1-IN-2 (Example 3) is a MuRF1 inhibitor. MuRF1-IN-2 can be used for research of muscle wasting conditions, of skeletal or cardial muscle atrophy .
    MuRF1-IN-2
  • HY-105318
    LGD-2226

    		Androgen Receptor Metabolic Disease Endocrinology
    LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction .
    LGD-2226
  • HY-111246
    MK-3984

    		Androgen Receptor Cancer
    MK-3984 is a selective androgen receptor modulator (SARM). MK-3984 can be used for the research of muscle wasting associated with cancer .
    MK-3984
  • HY-111044
    (+)-JNJ-37654032

    		Androgen Receptor Cancer
    (+)-JNJ-37654032 is an orally active and selective androgen receptor modulator. (+)-JNJ-37654032 can be used in the study of muscle-wasting diseases .
    (+)-JNJ-37654032
  • HY-182773
    MC4R Antagonist-1

    		Melanocortin Receptor Metabolic Disease
    MC4R Antagonist-1 (compound 1) is an MC4R-selective antagonist (IC50<10 nM). MC4R Antagonist-1 can be used for the research of cachexia, anorexia, anorexia nervosa, involuntary weight loss, failure to thrive, sarcopenia, muscle wasting, muscle weakness, frailty, osteoporosis .
    MC4R Antagonist-1
  • HY-105318R
    LGD-2226 (Standard)

    		Reference Standards Androgen Receptor Metabolic Disease Endocrinology
    LGD-2226 (Standard) is the analytical standard of LGD-2226 (HY-105318). This product is intended for research and analytical applications. LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction .
    LGD-2226 (Standard)
  • HY-N12385
    Hispaglabridin B

    (R)-Hispaglabridin B

    		 FOXO Others
    Hispaglabridin B is an anti-oxidant agent that can be isolated from Glycyrrhiza glabra. Hispaglabridin B exhibits potent peroxynitrite scavenging activity with an IC50 of 3.2 μM, and shows activity in a low-density lipoprotein (LDL) oxidation system . Hispaglabridin B is also a FoxO1 inhibitor . Hispaglabridin B improves muscle wasting by inhibiting catabolism in vivo and in vitro.
    Hispaglabridin B

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: